DOS-ACC-NOFO-2024-01: PEPFAR MEDIA TRAINING AND HIV ANTI-STIGMA PROGRAMS
Closed
This grant is closed. A newer notice from the same program is open now: Advancing Global Health (DFOP0017890). Status: Closes February 14, 2027 (99 days left). It is in our archive of U.S. Mission to Ghana notices from 2024.
U.S. Mission to Ghana offered grants of up to $40,000 (at least $30,000) to nonprofits. It expected to make about 2 awards worth $75,000 in total. Applications closed on July 30, 2024.
From the official notice on Grants.gov, last changed April 24, 2024. Checked November 7, 2026.
- Award ceiling$40,000
- Award floor$30,000
- Total funding$75,000
- Expected awards2
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| DOS-ACC-NOFO-2022-01 | June 1, 2022 | Closed July 29, 2022 | Closed |
Key dates
| Posted | April 24, 2024 |
|---|---|
| Deadline | July 30, 2024 |
| Archived by Grants.gov | July 31, 2024 |
Who can apply
This opportunity was open to nonprofits.
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Is this a realistic fit?
- Past The U.S. President's Emergency Plan for AIDS Relief Programs awards averaged $146,897; this notice allows up to $40,000 per award.
- Most of the program's money (74% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
PEPFAR Ghana is seeking two organizations to submit proposals to implement: MEDIA TRAINING - A training for selected journalists on HIV HIV ANTI- STIGMA CAMPAIGN - To organize community engagements with local Government and Traditional authorities on Stigma and discrimination to push forward the Test and Treat goal in eliminating HIV as a public health threat by 2030.
Who has won The U.S. President's Emergency Plan for AIDS Relief Programs grants before
From fiscal 2021 to 2025, The U.S. President's Emergency Plan for AIDS Relief Programs (19.029) awarded $117 million across 794 grant awards, an average of $146,897 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Maryland | 1 | $89.9 million |
| Miscellaneous Foreign Awardees | 321 | $7.9 million | |
| Ho Chi Minh City HIV/AIDS Association | 4 | $673,404 | |
| Tamra for Social Development Organization (TDS) | 3 | $638,998 | |
| National Empowerment Network of People Living with HIV / AIDS (Nephak) | 3 | $513,403 |
Applying now
This notice no longer takes applications. Apply under the newer notice, DFOP0017890, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is DOS-ACC-NOFO-2024-01 still open?
No. It closed on July 30, 2024. A newer notice is open: DFOP0017890, closes February 14, 2027 (99 days left).
Who can apply for PEPFAR MEDIA TRAINING AND HIV ANTI-STIGMA PROGRAMS?
U.S. Mission to Ghana accepted applications from nonprofits.
What is the deadline for PEPFAR MEDIA TRAINING AND HIV ANTI-STIGMA PROGRAMS?
Closed July 30, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $40,000 each. About $75,000 in total across about 2 awards.
Who has won The U.S. President's Emergency Plan for AIDS Relief Programs grants before?
The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Miscellaneous Foreign Awardees, Ho Chi Minh City HIV/AIDS Association. The program made 794 awards worth $117 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)